Nektar Therapeutics (NASDAQ:NKTR) Stake Lifted by Jane Street Group LLC

Jane Street Group LLC grew its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 50.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 91,470 shares of the biopharmaceutical company’s stock after buying an additional 30,481 shares during the period. Jane Street Group LLC’s holdings in Nektar Therapeutics were worth $119,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in NKTR. Victory Capital Management Inc. bought a new position in shares of Nektar Therapeutics in the second quarter valued at approximately $29,000. Valence8 US LP purchased a new stake in Nektar Therapeutics during the third quarter valued at about $34,000. Intech Investment Management LLC acquired a new stake in shares of Nektar Therapeutics in the third quarter worth $41,000. Erste Asset Management GmbH acquired a new position in Nektar Therapeutics in the 3rd quarter valued at approximately $61,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Nektar Therapeutics during the 3rd quarter valued at about $86,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on NKTR shares. BTIG Research reissued a “buy” rating and issued a $4.00 price target on shares of Nektar Therapeutics in a research report on Monday, September 30th. B. Riley initiated coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $4.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.50 price objective on shares of Nektar Therapeutics in a research note on Monday. Finally, Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price objective for the company. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Nektar Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $4.08.

Nektar Therapeutics Stock Down 6.4 %

Shares of Nektar Therapeutics stock opened at $0.90 on Wednesday. Nektar Therapeutics has a twelve month low of $0.48 and a twelve month high of $1.93. The stock has a market cap of $166.01 million, a price-to-earnings ratio of -1.07 and a beta of 0.59. The company’s fifty day moving average is $1.07 and its 200 day moving average is $1.21.

Insider Transactions at Nektar Therapeutics

In other news, insider Jonathan Zalevsky sold 51,115 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $0.94, for a total value of $48,048.10. Following the completion of the sale, the insider now directly owns 326,904 shares of the company’s stock, valued at $307,289.76. This represents a 13.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $0.90, for a total transaction of $30,061.80. Following the completion of the sale, the insider now owns 351,892 shares of the company’s stock, valued at approximately $316,702.80. The trade was a 8.67 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 155,575 shares of company stock valued at $149,878. Corporate insiders own 3.71% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.